CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate

Background: Glatiramer acetate (GA) is an effective treatment for the earliest stages of multiple sclerosis (MS)—clinically isolated syndrome (CIS) or clinically definite MS (CDMS). Objective: This study aims to determine the differences in the lymphocyte population (at baseline and the course of fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vališ, Martin, Sobíšek, Lukáš, Vyšata, Oldřich, Klímová, Blanka, Andrýs, Ctirad, Vokurková, Doris, Masopust, Jiří, Pavelek, Zbyšek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562382/
https://www.ncbi.nlm.nih.gov/pubmed/31096621
http://dx.doi.org/10.3390/cells8050456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562382/
https://www.ncbi.nlm.nih.gov/pubmed/31096621
http://dx.doi.org/10.3390/cells8050456

Ejemplares similares